Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response

Galit Eisenberg, Arthur Machlenkin*, Shoshana Frankenburg, Adva Mansura, Jacob Pitcovski, Eitan Yefenof, Tamar Peretz, Michal Lotem

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

The objective of this study was to evaluate the potential of transcutaneous immunization with tumor antigen to induce cell-mediated immunity. For this purpose, hydrophilic recombinant gp100 protein (HR-gp100) was topically applied on human intact skin in vitro, and used as a vaccine in a mouse model. We demonstrate that HR-gp100 permeates into human skin, and is processed and presented by human dendritic cells. In a mouse model, an HR-gp100-based vaccine triggered antigen-specific T cell responses, as shown by proliferation assays, ELISA and intracellular staining for IFN-γ. Transcutaneous antigen delivery may provide a safe, simple and effective method to elicit cell-mediated immunity.

Original languageEnglish
Pages (from-to)98-103
Number of pages6
JournalCellular Immunology
Volume266
Issue number1
DOIs
StatePublished - 2010

Keywords

  • Cancer vaccine
  • Gp100
  • Transcutaneous immunization

Fingerprint

Dive into the research topics of 'Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response'. Together they form a unique fingerprint.

Cite this